ranibizumab (Lucentis, Byooviz)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6]

Introduction

Ophthalmics: Lucentis; Biosimilar: Byooviz

Indications

Dosage

  • intavitreal injection of 0.3-0.5 mg monthly

Adverse effects

Mechanism of action

Notes

  • according to the Washington Post, this is the same drug as bevacizumab (Avastin) both produced by Genentech[3]

More general terms

More specific terms

References

  1. ↑ 1.0 1.1 Rosenfeld PJ et al Ranibizumab for neovascular age-related macular degeneration N Engl J Med 2006, 355:1419 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021318
    Brown DM et al Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1432 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021319
    Steinbrook R. The price of sight - Ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006, 355:1409 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021315
    Stone EM. A very effective treatment for neovascular macular degeneration N Engl J Med 2006, 355:1493 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021326
  2. ↑ 2.0 2.1 FDA News Release: Aug. 10, 2012 FDA approves Lucentis to treat diabetic macular edema http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315130.htm
  3. ↑ 3.0 3.1 Kliff S This $2,000 drug says everything about our messed up health- care system. Washington Post Dec 9, 2013 http://www.washingtonpost.com/blogs/wonkblog/wp/2013/12/09/this-2000-drug-says-everything-about-our-messed-up-health-care-system/
  4. ↑ Bressler NM, Doan QV, Varma R et al Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age- related macular degeneration. Arch Ophthalmol. 2011 Jun;129(6):709-17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21670337
  5. ↑ 5.0 5.1 5.2 FDA News Release. February 6, 2015 FDA approves Lucentis to treat diabetic retinopathy in patients with diabetic macular edema. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm433392.htm
  6. ↑ Bressler NM, Kim T, Oh I et al Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and PharmacokineticsA Post Hoc Analysis of a Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023;141(2):117-127. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36520462 PMCID: PMC9857301 Free PMC article https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2799737
Retrieved from "https://aaushi.info/w/index.php?title=A15865&oldid=1171971"